P. Kerschen, La sclérose en plaques : aperçu historique, La Lettre du Neurologue, vol.14, issue.2, pp.54-62, 2010.

J. M. Charcot, Leçons sur les maladies du système nerveux faites à la Salpêtrière (1872-1873), 2009.

B. Kornek and H. Lassmann, Axonal pathology in multiple sclerosis. A historical note, Brain Pathol, vol.9, issue.4, pp.651-657, 1999.

C. A. Beck, L. M. Metz, L. W. Svenson, and S. B. Patten, Regional variation of multiple sclerosis prevalence in Canada, Mult Scler, vol.11, issue.5, pp.516-525, 2005.

B. M. Kies, An epidemiological study of multiple sclerosis in Cape Town, Southafrica, Advances in Neurology: Proceedings of the 14th World Congress of Neurology, p.278, 1989.

C. P. Tsai, C. L. Yuan, H. Y. Yu, C. Chen, Y. C. Guo et al., Multiple sclerosis in Taiwan, J Chin Med Assoc, vol.67, issue.10, pp.500-505, 2004.

, Arsep Fondation Sclérose en plaques

. Paris, Définition et chiffres, 2016.

J. F. Kurtzke, A reassessment of the distribution of multiple sclerosis. Part one, Acta Neurol Scand, vol.51, issue.2, pp.110-146, 1975.

G. Rosati, The prevalence of multiple sclerosis in the world: an update, Neurol Sci, vol.22, issue.2, pp.117-156, 2001.

S. Simpson, L. Blizzard, P. Otahal, I. Van-der-mei, and B. Taylor, Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis, J Neurol Neurosur Ps, vol.82, issue.10, pp.1132-1173, 2011.

F. Lhermitte, A. Alperovitch, and O. Lyon-caen, Enquête sur la sclérose en plaques lancée par la télévision française, Rev Neurol, vol.14, issue.3, pp.135-141, 1988.

S. Vukusic, V. Van-bockstael, S. Gosselin, and C. Confavreux, Regional variations in the prevalence of multiple sclerosis in French farmers, J Neurol Neurosur Ps, vol.8, issue.7, pp.707-716, 2007.

A. Fromont, C. Binquet, E. A. Sauleau, I. Fournel, A. Bellisario et al., Geographic variations of multiple sclerosis in France, Brain, vol.133, issue.7, pp.1889-99, 2010.

E. Leray, T. Moreau, A. Fromont, and G. Edan, Epidemiology of multiple sclerosis, Rev Neurol, vol.172, issue.1, pp.3-13, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01255824

E. Leray, S. Vukusic, M. Debouverie, M. Clanet, B. Brochet et al., Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study Plos One, vol.10, 2015.

S. Kalson-ray, G. Edan, E. Leray, and . Group, An excessive risk of suicide may no longer be a reality for multiple sclerosis patients, Mult Scler, vol.23, issue.6, pp.864-71, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01518889

H. Brønnum-hansen, N. Koch-henriksen, and E. Stenager, Trends in survival and cause of death in Danish patients with multiple sclerosis, Brain, vol.127, issue.4, pp.844-50, 2004.

, Arsep Fondation Sclérose en plaques

. Paris, Le système nerveux, 2016.

M. Salou, E. Ngono, A. Garcia, A. Michel, L. Laplaud et al., Immunité adaptative et physiopathologie de la sclérose en plaques, Rev Med Interne, vol.34, issue.8, pp.479-86, 2013.

P. Vermersch, Immunologie de la sclérose en plaques : évolution des concepts, Rev Neurol, vol.164, issue.2, pp.138-184, 2008.

D. Dimitri, Sclérose en plaques : maladie inflammatoire ou dégénérative ? Neurologie, com, vol.1, issue.4, pp.110-117, 2009.

, Académie nationale de médecine

. Paris, Académie de médecine

, La sclérose en plaques : quelles possibilités de régénération ?, 2008.

L. K. Fisniku, P. A. Brex, D. R. Altmann, K. A. Miszkiel, C. E. Benton et al., Disability and T2 MRI lesions : a 20-year follow-up of patients with relapse onset of multiple sclerosis, Brain, vol.131, issue.3, pp.808-825, 2008.

T. Moreau and A. Fromont, La sclérose en plaques en, Images en Ophtalmologie, vol.8, issue.1, pp.10-16, 2014.

F. D. Lublin and S. C. Reingold, Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis, Neurology, vol.46, issue.4, pp.907-918, 1996.

R. Depaz, J. Aboab, and O. Gout, Update on diagnosis and treatment of multiple sclerosis, Rev Med Interne, vol.34, issue.10, pp.628-663, 2013.

R. Dutta and B. D. Trapp, Anatomopathologie et définition de la sclérose en plaques, Rev Praticien, vol.56, issue.12, pp.1293-98, 2006.

L. Magy, La sclérose en plaques, Actualités pharmaceutiques hospitalières, vol.5, pp.14-23, 2009.

F. D. Lublin, S. C. Reingold, J. A. Cohen, G. R. Cutter, P. S. Sørensen et al., Defining the clinical course of multiple sclerosis : the 2013 revisions, Neurology, vol.83, issue.3, pp.278-86, 2014.

J. Cambier, M. Masson, H. Dehen, and . Neurologie, , 2012.

C. Diaz-olavarrieta, J. L. Cummings, J. Velazquez, and C. Garcia-de-la-cadena, Neuropsychiatric manifestations of multiple sclerosis, J Neuropsychiatry Clin Neurosci, vol.11, issue.1, pp.51-58, 1999.

N. D. Chiaravalloti and J. Deluca, Cognitive impairment in multiple sclerosis, Lancet Neurol, vol.7, issue.12, pp.1139-51, 2008.

P. Gallien, B. Nicolas, and A. Guichet, Le point sur la sclérose en plaques. Kinésithérapie Rev, vol.12, pp.17-22, 2012.

E. Roullet, Evaluation clinique du suivi et de l'évolution, Rev Neurol, vol.157, issue.8, pp.1121-1124, 2001.

, Arsep Fondation Sclérose en plaques

. Paris, Les échelles d'évaluation de la SEP, p.106, 2016.

C. Scherer and F. Dubas, Sclérose en plaques, Rev Praticien, vol.59, issue.8, pp.695-701, 2009.

. Paris, Sclérose en plaques : définition et symptomatologie, 2015.

. Disponible,

O. Delaroche and B. Evreux, Bigot-Corbel E. Étude biochimique du liquide céphalorachidien dans le cadre de la sclérose en plaques, Immuno-Anal Biol Spe, vol.18, issue.2, pp.86-95, 2003.

W. I. Mcdonald, A. Compston, G. Edan, D. Goodkin, H. P. Hartung et al., Recommended diagnostic criteria for multiple sclerosis : guidelines from the International Panel on the diagnosis of multiple sclerosis, Ann Neurol, vol.50, issue.1, pp.121-128, 2001.

B. Audoin and O. Casez, Critères diagnostics de la sclérose en plaques, Neurologies, vol.15, issue.144, pp.18-26, 2012.

K. M. Myhr and S. I. Mellgren, Corticosteroids in the treatment of multiple sclerosis, Acta Neurol Scand, vol.189, issue.2, pp.73-80, 2009.

S. Lattanzi, C. Cagnetti, M. Danni, L. Provinciali, and M. Silvestrini, Oral and intravenous steroids for multiple sclerosis relapse : a systematic review and meta-analysis, J Neurol, vol.264, issue.8, pp.1697-704, 2017.

L. Page, E. Veillard, D. Laplaud, D. A. Hamonic, S. Wardi et al., Oral versus intravenous high-dose methylprednisolone for treatment of relapses in 107 patients with multiple sclerosis (COPOUSEP) : a randomised, controlled, doubleblind, non-inferiority trial, Lancet, vol.386, issue.9997, pp.974-982, 2015.

D. M. Wingerchuk and J. L. Carter, Multiple sclerosis : current and emerging diseasemodifying therapies and treatment strategies, Mayo Clin Proc, vol.89, issue.2, pp.225-265, 2014.

F. Taithe, Traitement des formes rémittentes, traitements actuels et à venir, Neurologies, vol.15, issue.148, pp.194-205, 2012.

J. Oh, O. Connor, and P. W. , An update of teriflunomide for treatment of multiple sclerosis, Ther Clin Risk Manag, vol.9, issue.2, pp.177-90, 2013.

A. Bayas and M. Mäurer, Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence, Patient Prefer Adher, vol.9, issue.4, pp.265-74, 2015.

A. Papadopoulou, M. Souza, and K. L. Diméthylfumarate, BG-12), Forum Med Suisse, vol.13, issue.38, pp.761-762, 2013.

R. J. Fox, D. H. Miller, J. T. Phillips, M. Hutchinson, E. Havrdova et al.,

, Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis, Study Investigators, vol.367, pp.1087-1097, 2012.

L. Michel, Mécanismes immunologiques des traitements de fond de la sclérose en plaques. Pratique neurologique, vol.7, pp.159-65, 2016.

M. Hutchinson, L. Kappos, P. A. Calabresi, C. Confavreux, G. Giovannoni et al., The efficacy of natalizumab in patients with relapsing multiple sclerosis : subgroup analyses of AFFIRM and SENTINEL, J Neurol, vol.256, issue.3, pp.405-420, 2009.

, ANSM

. Paris, Natalizumab (Tysabri®) : mise à jour des mesures de réduction du risque de LEMP-Lettre aux professionnels de santé, 2016.

J. A. Cohen, A. J. Coles, D. L. Arnold, C. Confavreux, E. J. Fox et al., CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis : a randomised controlled phase 3 trial, Lancet, vol.380, issue.9856, pp.1819-1847, 2012.

S. L. Hauser, A. Bar-or, G. Comi, G. Giovannoni, H. P. Hartung et al., Clinical Investigators of the OPERA I and OPERA II. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis, New Engl J Med, vol.376, issue.3, pp.221-255, 2017.

D. Lévy-chavagnat, De nouveaux atouts contre la SEP ? Actualités pharmaceutiques, vol.50, pp.21-25, 2011.

C. Bensa and O. Gout, Les immunomodulateurs dans la sclérose en plaques, Neurologie.com, vol.2, issue.3, pp.57-59, 2010.

H. Zéphir, J. De-seze, and O. Sénéchal, Traitement des formes progressives de sclérose en plaques par cyclophosphamide, Rev Neurol, vol.158, issue.1, pp.65-69, 2002.

D. Beckett, Biotin Sensing at the Molecular Level, J Nutr, vol.139, issue.1, pp.167-170, 2009.

A. Tourbah, C. Lebrun-frenay, G. Edan, M. Clanet, C. Papeix et al., MS-SPI study group. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis : A randomised, doubleblind, placebo-controlled study, Mult Scler, vol.22, issue.13, pp.1719-1750, 2016.

, ANSM

. Paris, Protocole d'utilisation thérapeutique et de recueil d'informations-QIZENDAY 100mg, gélule, 2016.

S. Haggiag, S. Ruggieri, and C. Gasperini, Efficacy and safety of laquinimod in multiple sclerosis : current status, Ther Adv Neurol Disord, vol.6, issue.6, pp.343-52, 2013.

, ANSM

. Paris, Agence nationale de sécurité du médicament et des produits de santé, 2013.

J. Dunn and A. Blight, Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis, Curr Med Res Opin, vol.27, issue.7, pp.1415-1438, 2011.

, World Health Organization [En ligne] Geneva (CH);1948. The First ten years of the World Health Organization

. Disponible,

A. Leplege and S. Hunt, The problem of quality of life in medicine, JAMA, vol.278, issue.1, pp.47-50, 1997.

, Ministère des Solidarité et de la Santé

. Paris, Plan 20072011 pour l'amélioration de la qualité de vie des patients atteints de maladies chroniques, 2007.

. Disponible,

F. Bacro, La qualité de vie, approches psychologies. PUR, 2014.

P. Erickson and D. L. Patrick, Guidelines for selecting quality of life assessment : methodological and practical consideration, J Drug Ther Res, vol.13, issue.5, pp.159-163, 1998.

G. Kemoun, C. Benaim, and A. Thevenon, Une approche de la qualité de vie : l'évaluation individualisée. Annales de réadaptation et de médecine physique, vol.39, pp.171-177, 1996.

J. L. Wallander, M. Schmitt, and H. M. Koot, Quality of life measurement in children and adolescents : issues, instruments and applications, J Clin Psychol, vol.4, issue.57, pp.571-85, 2001.

, World Health Organization. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL), Qual Life Res, vol.2, issue.2, pp.153-162, 1993.

D. A. Revicki, D. Osoba, D. Fairclough, I. Barofsky, R. Berzon et al., Recommendations on health-related quality of life research to support labeling and promotional claims in the United States, Qual Life Res, vol.9, issue.8, pp.887-900, 2000.

M. Mercier and S. Schraub, Journées de la Soiété Française de Sénologie et de Pathologie Mammaire, p.111, 2005.

D. L. Patrick and P. Erickson, Quality of life in health care evaluation and resource allocation, vol.2, pp.478-487, 1993.

I. B. Wilson and P. D. Cleary, Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes, JAMA Neurol, vol.273, issue.1, pp.59-65, 1995.

C. E. Ferrans, J. J. Zerwic, J. E. Wilbur, and J. L. Larson, Conceptual model of health-related quality of life, J Nurs Scholarship, vol.37, issue.4, pp.336-378, 2005.

J. Coste and A. Leplège, Mesure de la santé perceptuelle et de la qualité de vie : méthodes et applications, 2002.

C. Brousse and B. Boisaubert, La qualité de vie et ses mesures, Rev Med Interne, vol.28, issue.7, pp.458-62, 2007.
DOI : 10.1016/j.revmed.2007.02.010

, Qaulity of life, 2000.

M. C. Siméoni, P. Auquier, J. C. Delaroziere, and A. Beresniak, Evaluation de la ualité de vie chez l'enfant et l'adolescent : qualité de vie et santé. La presse médicale, vol.28, pp.1033-1072, 1999.

R. A. Rudick and D. M. Miller, Health-related quality of life in multiple sclerosis: current evidence, measurement and effects of disease severity and treatment, CNS Drugs, vol.22, issue.10, pp.827-866, 2008.

A. J. Mitchell, J. Benito-león, J. González, and J. Rivera-navarro, Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing, Lancet Neurol, vol.4, issue.9, pp.556-66, 2005.

J. Greenhalgh, A. F. Long, and R. Flynn, The use of patient reported outcome measures in routine clinical practice: lackof impact or lack of theory?, Soc Sci Med, vol.60, issue.4, pp.833-876, 2005.

C. J. Nowinski, D. M. Miller, and D. Cella, Evolution of Patient-Reported Outcomes and Their Role in Multiple Sclerosis Clinical Trials, Neurotherapeutics, vol.14, issue.4, pp.934-978, 2017.

M. S. Deloire, E. Salort, M. Bonnet, Y. Arimone, M. Boudineau et al., Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis, J Neurol Neurosur Ps, vol.76, issue.4, pp.519-545, 2005.

P. Clavelou, C. Auclair, F. Taithe, and L. Gerbaud, La qualité de vie des patients souffrant de sclérose en plaques, Revue Neurologique, vol.165, issue.4, pp.123-131, 2009.

A. Janssens, P. A. Van-doorn, J. B. Boer, F. Van-der-meché, J. Passchier et al., Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners, Acta Neurol Scand, vol.108, issue.6, pp.389-95, 2003.

D. Vernay, L. Gerbaud, S. Biolay, J. Coste, J. Debourse et al., Quality of life and multiple sclerosis: validation of the french version of the selfquestionnaire (SEP-59), Rev Neurol, vol.156, issue.3, pp.247-63, 2000.

(. Bethesda and . Md, Multiple Sclerosis" AND "Quality of life, 2000.

. Disponible,

D. A. Gruenewald, I. J. Higginson, B. Vivat, P. Edmonds, and R. E. Burman, Quality of life measures for the palliative care of people severely affected by multiple sclerosis : a systematic review, Mult Scler, vol.10, issue.6, pp.690-725, 2004.

K. Baumstarck, L. Boyer, M. Boucekine, P. Michel, J. Pelletier et al., Measuring the Quality of Life in Patients with Multiple Sclerosis in Clinical Practice: A Necessary Challenge, Mult Scler Int, vol.8, issue.20, pp.1-8, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01096974

M. W. Nortvedt, T. Riise, K. M. Myhr, and H. I. Nyland, Quality of life as a predictor for change in disability in MS, Neurology, vol.55, issue.1, pp.51-55, 2000.

M. A. Visschedijk, B. M. Uitdehaag, M. Klein, E. Van-der-ploeg, E. H. Collette et al., Value of health-related quality of life to predict disability course in multiple sclerosis, Neurology, vol.63, issue.11, pp.2046-50, 2004.

K. Baumstarck, J. Pelletier, H. Butzkueven, O. Fernández, P. Flachenecker et al., MusiQoL study group. Health-related quality of life as an independent predictor of long-term disability for patients with relapsing-remitting multiple sclerosis, Eur J Neurol, vol.20, issue.6, pp.907-921, 2013.

O. Fernandez, K. Baumstarck-barrau, M. C. Simeoni, and P. Auquier, Patient characteristics and determinants of quality of life in an international population with multiple sclerosis: assessment using the MusiQoL and SF-36 questionnaires, Mult Scler, vol.17, issue.10, pp.1238-1287, 2011.

J. Reboul-marty and R. Launois, Les Indicateurs de Qualité de Vie : processus de Mesure et Validation. Cardioscopies, vol.12, pp.635-672, 1995.

B. G. Vickrey, R. D. Hays, R. Harooni, L. W. Myers, and G. W. Ellison, A health-related quality of life measure for multiplesclerosis, Qual Life Res, vol.4, issue.3, pp.187-206, 1995.

L. Nicholl, J. C. Hobart, A. F. Cramp, and A. S. Lowe-strong, Measuring quality of life in multiple sclerosis: not as simple as it sounds, Mult Scler, vol.11, issue.6, pp.708-712, 2005.

K. Baumstarck-barrau, J. Pelletier, M. C. Simeoni, and P. Auquier, French validation of the MultIple Sclerosis International Quality of Life Questionnaire, Rev Neurol, vol.167, issue.6-7, pp.511-532, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00617047

O. Fernandez, V. Fernandez, K. Baumstarck-barrau, L. Muñoz, G. Alvarez-mdel et al.,

. Spain, Validation of the spanish version of the Multiple Sclerosis International Quality of Life (Musiqol) questionnaire, BMC Neurol, vol.11, issue.2, p.127, 2011.

P. Flachenecker, U. Vogel, M. C. Simeoni, P. Auquier, and P. Rieckmann, MusiQol: international questionnaire investigating quality of life in multiple sclerosis: Validation results for the German subpopulation in an international comparison

, Nervenarzt, vol.82, issue.10, pp.1281-1290, 2011.